Funding sources None.
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts
Article first published online: 5 OCT 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 1, pages 129–135, January 2013
How to Cite
Antonelli, A., Ferri, C., Ferrari, S.M., Colaci, M., Ruffilli, I., Sebastiani, M. and Fallahi, P. (2013), Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts. British Journal of Dermatology, 168: 129–135. doi: 10.1111/j.1365-2133.2012.11199.x
Conflicts of interest None declared.
- Issue published online: 21 DEC 2012
- Article first published online: 5 OCT 2012
- Accepted manuscript online: 4 AUG 2012 10:00AM EST
- Accepted for publication 31 July 2012
Background No study has evaluated the effect of the peroxisome proliferator-activated receptor γ (PPARγ) agonists on cell viability, proliferation and apoptosis in cultured systemic sclerosis (SSc) fibroblasts.
Objectives The effects of two pure PPARγ agonists (rosiglitazone and pioglitazone) in cultured SSc fibroblasts were evaluated and compared with effects in normal fibroblasts.
Methods The study included evaluation of cell viability and proliferation (based on the cleavage of tetrazolium salts and measurement of absorbance of the cell proliferation reagent WST-1), and determination of cell apoptosis (by means of the Hoechst dye uptake).
Results Rosiglitazone or pioglitazone (20 μmol L−1) significantly reduced cell proliferation (cell count of 75% and 83% compared with baseline, respectively, after 2 h) and cell viability (absorbance reductions of 25% and 22% compared with baseline, respectively, after 2 h), and increased apoptosis (apoptotic cell percentages 9·9% and 8·6%, respectively, after 48 h of incubation) in SSc fibroblasts, whereas they did not present a significant influence on control fibroblasts.
Conclusions The effects of rosiglitazone or pioglitazone shown on SSc fibroblasts raise the hypothesis of a therapeutic role for PPARγ agonists in patients affected by SSc.